A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
Braz. j. infect. dis
; 15(5): 498-500, Sept.-Oct. 2011.
Article
em En
| LILACS
| ID: lil-612714
Biblioteca responsável:
BR1.1
ABSTRACT
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Sulfonamidas
/
Infecções por HIV
/
Inibidores da Protease de HIV
/
Ritonavir
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Braz. j. infect. dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2011
Tipo de documento:
Article